Inactive Instrument

Oxford BioMedica plc Share Price London S.E.

Equities

GB0006648157_GB

GB0006648157

Biotechnology & Medical Research

Financials

Sales 2023 89.54M 112M 9.33B Sales 2024 * 130M 162M 13.53B Capitalization 277M 346M 28.8B
Net income 2023 -157M -196M -16.35B Net income 2024 * -35M -43.78M -3.65B EV / Sales 2023 2.38 x
Net cash position 2023 * 49.23M 61.57M 5.13B Net cash position 2024 * 13.8M 17.26M 1.44B EV / Sales 2024 * 2.02 x
P/E ratio 2023
-1.35 x
P/E ratio 2024 *
-8.39 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.81%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 27/23/27
Director of Finance/CFO 52 29/17/29
Chairman 68 24/20/24
Members of the board TitleAgeSince
Director/Board Member 61 01/23/01
Chairman 68 24/20/24
Director/Board Member 66 01/16/01
More insiders
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
More about the company
  1. Stock Market
  2. Equities
  3. OXB Stock
  4. GB0006648157_GB Stock